Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A 23-year-old male shared his 6-month hair transformation using Dutasteride, oral Minoxidil, ketoconazole shampoo, vitamin D, gym, cardio, and dermastamping. He reported significant hair maintenance and no side effects.

A user stopped finasteride due to side effects and rapid hair loss, considering a hair system. Others suggested alternatives like dutasteride, minoxidil, and topical finasteride.

The conversation is about the role of vitamin deficiencies in hair loss and the effectiveness of treatments like Minoxidil, finasteride, and RU58841. It concludes that while vitamins and nutrition are important, they are not the primary solution for androgenic alopecia.

A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A 26-year-old man from France started experiencing hair loss in September 2020 and began using finasteride in June 2021, reporting some improvement after three months without side effects. He plans to continue finasteride for a year before considering additional treatments like minoxidil or dermarolling.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

A user needs to stop finasteride for 7 days to donate blood due to haemochromatosis. They are concerned if this break will affect their hair loss progress after 6 weeks of use.

The conversation discusses using daily microneedling at 0.25mm and red light therapy to enhance hair regrowth, especially when traditional treatments like finasteride and minoxidil become less effective. The combination is said to improve hair density and thickness, with red light therapy being more cosmetic, while microneedling is essential for challenging areas.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conclusion of the conversation is that the user started using 5% Minoxidil for hair loss and is happy with the progress. They also mentioned being trans and coming off testosterone, which they believe will help prevent further hair loss. Some users suggested using finasteride as well.

Creatine might increase DHT levels, potentially affecting hair loss, but its impact is debated. Some users experience hair shedding with creatine despite using finasteride, while others notice no change.

The conversation is about severe Vitamin D deficiency and its potential link to hair loss. The user is already using oral finasteride, topical finasteride, and topical minoxidil for aggressive hair loss.

A 24-year-old male has been using oral Minoxidil (2.5mg daily) and daily Dutasteride for hair loss, noticing slight thickening but no major regrowth. Users suggest increasing Minoxidil dosage to 5mg and maintaining consistency, with some recommending additional treatments like topical Minoxidil or considering a hair transplant in the future.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

Oral minoxidil is discussed, highlighting potential cardiovascular risks at high doses, but users note that lower doses commonly used for hair loss are generally considered safe. Monitoring by doctors is advised, and some users report taking it without issues, comparing its risks to those of common medications like ibuprofen.

Taking dutasteride daily at higher doses results in more effective DHT suppression compared to every other day dosing, due to its dose-dependent nature and long half-life. Even at lower doses, dutasteride is more effective than finasteride for hair loss.

A user shared progress pictures after 15 months on 0.5 mg finasteride, reporting significant hair regrowth starting around 9 months. They no longer see the need for a hair transplant.

The user switched from topical minoxidil/dutasteride to oral dutasteride, resulting in hair loss. They resumed topical treatment without regrowth and are considering switching to finasteride due to poor results with oral dutasteride.

A user shared their positive experience with finasteride over 1.5 years, noting significant hair regrowth and no side effects. They also mentioned unsuccessful attempts with minoxidil and are considering a hair transplant to improve their hairline.

The conversation discusses the pros and cons of dutasteride for male pattern baldness, with a focus on its long half-life. The user, a physician, also mentions that switching from finasteride to dutasteride can cause temporary hair loss until dutasteride reaches effective levels or accelerates the hair cycle.

A user is using oral finasteride, oral dutasteride, and drinking topical minoxidil for hair loss, despite health warnings. Switching from finasteride to dutasteride did not improve hair density.

The conversation is about the use of microneedling, specifically with a derma stamp, for hair regrowth. Users discuss their experiences, pain levels, and the satisfaction of taking control over hair loss, with some mentioning the use of Minoxidil to enhance results.

A user created oral minoxidil sugar cubes due to lack of prescription access, leading to a humorous discussion about unconventional and potentially unsafe methods of using minoxidil. The conversation highlights the lengths people go to for hair growth.

User "manlycoffee" shares 25-month progress using Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral, T/GEL, and fixing vitamin D levels for hair loss. Users discuss sources, experiences, and side effects of treatments.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.